Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Study of Osteopontin as a Marker of Arteriovenous Shunt Stenosis in Hemodialysis Patients

Author(s): Marwa R. Elbarbary, Laila A. Ahmed*, Doaa A. El-Adl, Alshimaa A. Ezzat and Sherif A. Nassib

Volume 22, Issue 1, 2024

Published on: 30 November, 2023

Page: [50 - 57] Pages: 8

DOI: 10.2174/0115701611260120231106081701

Price: $65

conference banner
Abstract

Introduction: Although arteriovenous fistula (AVF) is the recommended access for hemodialysis (HD), it carries a high risk for stenosis. Since osteopontin (OPN) is implicated in the process of vascular calcification in HD patients, OPN may be a marker for AVF stenosis. The present study evaluated OPN as a potential marker of AVF stenosis in HD patients.

Methods: Diagnosing a stenotic lesion was made by combining B mode with color and pulse wave Doppler imaging. Criteria for diagnosis of stenotic AVF included 50% reduction in diameter in B mode in combination with a 2-3-fold increase of peak systolic velocity compared with the unaffected segment.

Results: The present study included 60 HD patients with stenotic AVF and 60 patients with functional AVF. Comparison between the two groups revealed that patients in the former group had significantly higher serum OPN levels [median (IQR): 17.1 (12.1-30.4) vs 5.8 (5.0-10.0) ng/mL, p<0.001]. All patients were classified into those with low (< median) and with high (≥ median) OPN levels. Comparison between these groups revealed that the former group had a significantly lower frequency of stenotic AVF (31.7 vs 68.3%, p<0.001) and a longer time to AVF stenosis [mean (95% CI): 68.4 (54.7-82.1) vs 46.5 (39.6-53.4) months, p=0.001].

Conclusion: OPN levels in HD patients may be useful markers for predicting and detecting AVF stenosis.

« Previous Next »
Graphical Abstract

[1]
Hashmi MF, Benjamin O, Lappin SL. End-Stage Renal Disease. StatPearls 2023.
[2]
Wouk N. End-stage renal disease: Medical management. Am Fam Physician 2021; 104(5): 493-9.
[PMID: 34783494]
[3]
Fila B. Quality indicators of vascular access procedures for hemodialysis. Int Urol Nephrol 2021; 53(3): 497-504.
[http://dx.doi.org/10.1007/s11255-020-02609-5] [PMID: 32869172]
[4]
Lawson JH, Niklason LE, Roy-Chaudhury P. Challenges and novel therapies for vascular access in haemodialysis. Nat Rev Nephrol 2020; 16(10): 586-602.
[http://dx.doi.org/10.1038/s41581-020-0333-2] [PMID: 32839580]
[5]
Pinto R, Sousa C, Salgueiro A, Fernandes I. Arteriovenous fistula cannulation in hemodialysis: A vascular access clinical practice guidelines narrative review. J Vasc Access 2022; 23(5): 825-31.
[6]
Gameiro J, Ibeas J. Factors affecting arteriovenous fistula dysfunction: A narrative review. J Vasc Access 2020; 21(2): 134-47.
[PMID: 31113281]
[7]
Al-Jaishi AA, Liu AR, Lok CE, Zhang JC, Moist LM. Complications of the arteriovenous fistula: A systematic review. J Am Soc Nephrol 2017; 28(6): 1839-50.
[http://dx.doi.org/10.1681/ASN.2016040412] [PMID: 28031406]
[8]
Raksasuk S, Naweera W, Rojwatcharapibarn S, Srithongkul T. Comparing non-invasive diagnostic methods for arteriovenous fistula stenosis: A prospective study. J Ultrasound 2022; 26(3): 687-93.
[http://dx.doi.org/10.1007/s40477-022-00731-x] [PMID: 36319839]
[9]
Oh DJ, Lee JH, Kwon YE, Choi HM. Relationship between arteriovenous fistula stenosis and circulating levels of neutrophil granule proteins in chronic hemodialysis patients. Ann Vasc Surg 2021; 77: 226-35.
[http://dx.doi.org/10.1016/j.avsg.2021.05.056] [PMID: 34437969]
[10]
Li C, Li Q, Ou J, et al. Relationship between monocytes and stenosis-related autologous arteriovenous fistula dysfunction. Blood Purif 2022; 51(3): 226-32.
[http://dx.doi.org/10.1159/000514059] [PMID: 34111871]
[11]
Ruan L, Yao X, Li W, et al. Effect of galectin-3 in the pathogenesis of arteriovenous fistula stenosis formation. Ren Fail 2021; 43(1): 566-76.
[http://dx.doi.org/10.1080/0886022X.2021.1902822] [PMID: 33757402]
[12]
Kaleta B. The role of osteopontin in kidney diseases. Inflamm Res 2019; 68(2): 93-102.
[http://dx.doi.org/10.1007/s00011-018-1200-5] [PMID: 30456594]
[13]
Johri P, Singh S, Sao P, et al. An integrated approach to identify intrinsically disordered regions in osteopontin with its interacting network in rheumatoid arthritis. Recent Adv Anti-Infect Drug Discov 2023; 18(1): 69-86.
[http://dx.doi.org/10.2174/2772434417666220908122654] [PMID: 36089787]
[14]
Maniatis K, Siasos G, Oikonomou E, et al. osteoprotegerin and osteopontin serum levels are associated with vascular function and inflammation in coronary artery disease patients. Curr Vasc Pharmacol 2020; 18(5): 523-30.
[http://dx.doi.org/10.2174/1570161117666191022095246] [PMID: 31642412]
[15]
Yazici O, Dogan M, Ozal G, et al. Osteopontin is a prognostic factor in patients with advanced gastric cancer. Comb Chem High Throughput Screen 2021; 24(8): 1229-35.
[http://dx.doi.org/10.2174/1386207323666200902135349] [PMID: 32881660]
[16]
Behairy MA, Shawky S, Hamed R, Bawady S, Abdelsattar HA, Bichari W. Is serum Osteopontin a predictor of carotid atherosclerosis severity among prevalent hemodialysis patients? Clin Investig Arterioscler 2022; 34(2): 75-85.
[PMID: 35144845]
[17]
Hall MR, Yamamoto K, Protack CD, et al. Temporal regulation of venous extracellular matrix components during arteriovenous fistula maturation. J Vasc Access 2015; 16(2): 93-106.
[http://dx.doi.org/10.5301/jva.5000290] [PMID: 25262757]
[18]
Sadaghianloo N, Contenti J, Dufies M, et al. Co-culture of human fibroblasts, smooth muscle and endothelial cells promotes osteopontin induction in hypoxia. J Cell Mol Med 2020; 24(5): 2931-41.
[http://dx.doi.org/10.1111/jcmm.14905] [PMID: 32032472]
[19]
Contenti J, Durand M, Vido S, et al. Plasmatic osteopontin and vascular access dysfunction in hemodialysis patients: a cross-sectional, case–control study (The OSMOSIS Study). J Nephrol 2022; 35(2): 527-34.
[http://dx.doi.org/10.1007/s40620-021-01129-4] [PMID: 34468976]
[20]
Chan JS, Hsiao PJ, Chiang WF, Roy-Chaudhury P. The role of oxidative stress markers in predicting acute thrombotic occlusion of haemodialysis vascular access and progressive stenotic dysfunction demanding angioplasty. Antioxidants 2021; 10(4): 569.
[http://dx.doi.org/10.3390/antiox10040569] [PMID: 33917703]
[21]
Stirbu O, Gadalean F, Pitea IV, et al. C-reactive protein as a prognostic risk factor for loss of arteriovenous fistula patency in hemodialyzed patients. J Vasc Surg 2019; 70(1): 208-15.
[http://dx.doi.org/10.1016/j.jvs.2018.10.100] [PMID: 30792061]
[22]
Carbone F, Dallegri F, Montecucco F, et al. Serum osteopontin negatively impacts on intima-media thickness in patients with systemic lupus erythematosus. Eur J Clin Invest 2019; 49(5): e13089.
[http://dx.doi.org/10.1111/eci.13089] [PMID: 30767212]
[23]
Yan Y, Jiang F, Lai Y, et al. Effect of thyrotropin on osteopontin, integrin αvβ3, and VCAM-1 in the endothelium via activation of Akt. Int J Mol Sci 2016; 17(9): 1484.
[http://dx.doi.org/10.3390/ijms17091484] [PMID: 27657042]
[24]
Pei Z, Okura T, Nagao T, et al. Osteopontin deficiency reduces kidney damage from hypercholesterolemia in Apolipoprotein E-deficient mice. Sci Rep 2016; 6(1): 28882.
[http://dx.doi.org/10.1038/srep28882] [PMID: 27353458]
[25]
Varım C, Demirci T, Cengiz H, et al. Relationship between serum osteopontin levels and the severity of COVID-19 infection. Wien Klin Wochenschr 2021; 133(7-8): 298-302.
[http://dx.doi.org/10.1007/s00508-020-01789-5] [PMID: 33369698]
[26]
Nawaz SS, Siddiqui K, Mujammami M, Alotaibi O, Alanazi SS, Rafiullah M. Determinant of osteopontin levels in microvascular complications in patients with diabetes. Int J Gen Med 2022; 15: 4433-40.
[http://dx.doi.org/10.2147/IJGM.S354220] [PMID: 35509601]
[27]
Carbone F, Montecucco F. Osteopontin in cardiometabolic medicine: A risk stratification biomarker with future therapeutic implication. Curr Med Chem 2022; 29(25): 4314-6.
[http://dx.doi.org/10.2174/0929867329666211228113716] [PMID: 34963431]
[28]
Nakamachi T, Nomiyama T, Gizard F, et al. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes 2007; 56(6): 1662-70.
[http://dx.doi.org/10.2337/db06-1177] [PMID: 17360982]
[29]
Tanaka N, Momiyama Y, Ohmori R, et al. Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 26(8): e129-30.
[http://dx.doi.org/10.1161/01.ATV.0000229701.42828.73] [PMID: 16857954]
[30]
Birch N, Fillaus J, Florescu MC. The effect of statin therapy on the formation of arteriovenous fistula stenoses and the rate of reoccurrence of previously treated stenoses. Hemodial Int 2013; 17(4): 586-93.
[http://dx.doi.org/10.1111/j.1542-4758.2012.00762.x] [PMID: 23078106]
[31]
Chang HH, Chang YK, Lu CW, et al. Statins improve long term patency of arteriovenous fistula for hemodialysis. Sci Rep 2016; 6(1): 22197.
[http://dx.doi.org/10.1038/srep22197] [PMID: 26902330]
[32]
Martinez L, Duque JC, Escobar LA, et al. Distinct impact of three different statins on arteriovenous fistula outcomes: A retrospective analysis. J Vasc Access 2016; 17(6): 471-6.
[http://dx.doi.org/10.5301/jva.5000612] [PMID: 27768209]
[33]
Janardhanan R, Yang B, Vohra P, et al. Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model. Kidney Int 2013; 84(2): 338-52.
[http://dx.doi.org/10.1038/ki.2013.112] [PMID: 23636169]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy